Zevra Therapeutics Gestione
Criteri Gestione verificati 3/4
Zevra Therapeutics Il CEO è Neil McFarlane, nominato in Oct2023, e ha un mandato di 2.75 anni. la retribuzione annua totale è $ 3.78M, composta da 19.3% di stipendio e 80.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.66% delle azioni della società, per un valore di $ 3.73M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.5 anni e 3.3 anni.
Informazioni chiave
Neil McFarlane
Amministratore delegato
US$3.8m
Compenso totale
| Percentuale dello stipendio del CEO | 19.28% |
| Mandato del CEO | 2.8yrs |
| Proprietà del CEO | 0.7% |
| Durata media del management | 2.5yrs |
| Durata media del Consiglio di amministrazione | 3.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Jul 24
CHMP/EMA Refusal & Financial Risk Analysis
Zevra Therapeutics received a negative opinion (refusal) from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application (MAA) for Meplyffa (arimoclomol) for the treatment of Niemann-Pick disease type C (NPC). Following the announcement, the stock reacted with an immediate ~30% decline, dropping to the $8.56 level.Seeking Alpha • Jul 23
Zevra Therapeutics: Worthy Of An Initial Holding
Summary Zevra Therapeutics surged after Miplyffa’s patent was listed in the FDA Orange Book, granting exclusivity through 2041. ZVRA achieved FY25 net sales of $87.4M, moved into profitability, retired all debt, and now holds $236.8M in cash and investments. The pipeline is focused on late-stage celiprolol for VEDS, with no clinical competition and FDA Orphan and Breakthrough Therapy designations. Trading at ~9x FY27E EPS (net of cash), ZVRA offers expansion potential, a clean balance sheet, and possible takeout appeal—supporting a small purchase. Read the full article on Seeking Alpha
Nuova narrativa • Jul 20
Zevra Therapeutics: Galloping Through a Green Safari
From Prodrugs to a Rare Disease Powerhouse Zevra Therapeutics wasn’t always a rare disease contender. Originally known as KemPharm , the company spent years focused on prodrug technology for ADHD and pain management.
Aggiornamento narrativa • Jul 02
ZVRA: Extended Patent Exclusivity May Support Longer NPC Revenue Runway
The analyst price target for Zevra Therapeutics has shifted from $18 to $21, with analysts pointing to extended Miplyffa patent exclusivity and updated cash flow assumptions as key drivers of their higher valuation work. Analyst Commentary on Zevra Therapeutics Recent Street research on Zevra Therapeutics has focused on how extended Miplyffa intellectual property coverage could affect long term cash flow modeling, with several firms updating their price targets and assumptions around the duration of exclusivity.
Aggiornamento narrativa • Jun 18
ZVRA: Extended Rare Disease IP Runway Will Drive Future Upside Potential
Analysts have raised the fair value estimate for Zevra Therapeutics to $35 from $26, aligning it with updated Street price targets in the $27 to $35 range, as they incorporate extended Miplyffa intellectual property protection and a higher future P/E assumption into their models. Analyst Commentary Recent research updates on Zevra Therapeutics cluster around one theme: bullish analysts are reassessing the stock’s upside as they factor in longer intellectual property protection for Miplyffa and refine their cash flow models.
Nuova narrativa • Jun 09
Discounted Exit Multiple Approach (DEM)
Disclaimer: This financial analysis is for informational purposes only and does not constitute investment advice. Zevra Therapeutics is a rare disease pharmaceutical company fundamentally driven by a single commercial product.Aggiornamento narrativa • Jun 03
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have raised their average price target for Zevra Therapeutics to $23 from $22, citing early Miplyffa adoption trends, positive views on potential expansion opportunities, and ongoing adjustments to growth, margin and P/E assumptions in their models. Analyst Commentary Bullish analysts are leaning into a constructive view on Zevra Therapeutics, framing the updated US$23 average price target as grounded in observable Miplyffa adoption trends and modeled upside from expansion opportunities.Aggiornamento narrativa • Apr 23
ZVRA: NPC Diagnosis Expansion And EU Decision Will Drive Future Upside Potential
Narrative Update: Zevra Therapeutics The updated analyst price target for Zevra Therapeutics is now $23, a $1 increase, as analysts point to the launch progress of Miplyffa, expectations for continued U.S. market penetration, and potential future catalysts including EU approval, patent term extension, and celiprolol development in VEDS. Analyst Commentary Bullish analysts are highlighting Zevra Therapeutics as a name where current valuation is closely linked to the rollout of Miplyffa and a set of identifiable potential catalysts.Aggiornamento narrativa • Apr 08
ZVRA: NPC Diagnosis Expansion Will Drive Future Upside Potential
Analysts have maintained Zevra Therapeutics' fair value estimate at $26.00, with slight tweaks to growth, margin, and future P/E assumptions. Recent Street research highlights a $23 price target, supported by views that current pricing reflects conservative Miplyffa adoption and potential upside from broader patient reach and future regulatory or pipeline milestones.Aggiornamento narrativa • Mar 24
ZVRA: Expanding NPC Diagnosis And EU Decision Will Drive Future Upside
Analysts have kept Zevra Therapeutics' fair value estimate steady at $26.00 while updating their assumptions on Miplyffa's launch trajectory and potential upside from EU approval, expanded U.S. adoption, and celiprolol optionality, which they note is reflected in Street price targets moving toward $23.00. Analyst Commentary Bullish analysts are framing Zevra's current share price as tied closely to conservative expectations for Miplyffa, largely anchored to the already diagnosed U.S. Niemann Pick type C population.Aggiornamento narrativa • Mar 10
ZVRA: Growing NPC Access And Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their $26.00 price target for Zevra Therapeutics, citing updated assumptions that reflect slightly different estimates for revenue growth, profit margins, and future P/E, without materially changing their overall view of the stock's valuation. What's in the News Zevra Therapeutics appointed Justin Renz as Chief Financial Officer, effective March 9, 2026.Aggiornamento narrativa • Feb 24
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have kept their Zevra Therapeutics price target steady at $26.00. This points to largely unchanged fair value assumptions, even as they refine inputs such as revenue growth, profit margins and future P/E expectations.Aggiornamento narrativa • Feb 09
ZVRA: Expanded Access And NPC Data Will Support Long-Term Rare Disease Upside
Analysts have maintained their price target on Zevra Therapeutics at $26.00, citing only modest tweaks to assumptions around revenue growth, profit margins, the discount rate, and future P/E that did not materially change their overall view. What's in the News Zevra presented four posters at the 22nd Annual WORLDSymposium highlighting new data on MIPLYFFA (arimoclomol) for Niemann Pick Disease Type C.Aggiornamento narrativa • Jan 26
ZVRA: Expanded Access Deal Will Support Long-Term Rare Disease Upside
Narrative Update: Zevra Therapeutics Analyst Price Target The analyst price target for Zevra Therapeutics is now set at US$26.00. Analysts cite small adjustments to revenue growth assumptions, profit margin expectations, and future P/E estimates as key drivers for the updated view.Aggiornamento narrativa • Jan 11
ZVRA: Expanded Rare Disease Access Agreement Will Support Long-Term Upside
Analysts have maintained their price target for Zevra Therapeutics at US$26.00, citing only modest adjustments to assumptions around revenue growth, profit margins and future P/E. Taken together, these changes do not alter their overall view of the company’s valuation.Aggiornamento narrativa • Dec 26
ZVRA: Future Rare Disease Portfolio Will Support Long-Term Upside
Analysts have modestly increased their price target on Zevra Therapeutics to $26.00 per share, citing slightly stronger long term revenue growth and profit margin assumptions, alongside a marginally lower projected future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Aggiornamento narrativa • Dec 12
ZVRA: Future Rare Disease Approvals Will Drive Long-Term Upside
Analysts have reduced their price target on Zevra Therapeutics by 3.00 dollars to 26.00 dollars, citing expectations for slower revenue growth, slightly lower profit margins, and a modestly higher discount rate, partially offset by a lower anticipated future price to earnings multiple. What's in the News Chief Financial Officer and Treasurer R.Articolo di analisi • Nov 08
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a mediocre week for Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders, with the stock dropping 13% to...Articolo di analisi • Nov 03
Zevra Therapeutics (NASDAQ:ZVRA) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Sep 08
What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have had a horrible month, losing 26% after a relatively good period...Articolo di analisi • Jul 10
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 26% gain in the last month...Articolo di analisi • May 22
Revenues Tell The Story For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) As Its Stock Soars 26%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shareholders would be excited to see that the share price has had a great...
Nuova narrativa • Apr 29
MIPLYFFA Launch Will Spark European Expansion In 2025
Successful MIPLYFFA launch and European expansion plans indicate potential revenue growth and stable streams through strong demand and patient engagement.Articolo di analisi • Mar 10
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...Articolo di analisi • Nov 15
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
As you might know, Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) last week released its latest third-quarter, and things did...Articolo di analisi • Aug 30
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Zevra Therapeutics, Inc. ( NASDAQ:ZVRA ) shares have continued their recent momentum with a 34% gain in the last month...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$117m |
| Dec 31 2025 | US$4m | US$729k | US$78m |
| Sep 30 2025 | n/a | n/a | US$30m |
| Jun 30 2025 | n/a | n/a | -US$3m |
| Mar 31 2025 | n/a | n/a | -US$92m |
| Dec 31 2024 | US$5m | US$700k | -US$106m |
| Sep 30 2024 | n/a | n/a | -US$90m |
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
Compensazione vs Mercato: La retribuzione totale di Neil ($USD 3.78M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.45M ).
Compensazione vs guadagni: La retribuzione di Neil è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Neil McFarlane (53 yo)
2.8yrs
Mandato
US$3,782,042
Compensazione
Mr. Neil F. McFarlane serves as the Member of Board of Managers of HCRx Holdings at Healthcare Royalty Management, LLC. He is in this position since January 2024. He serves as President & Chief Executive O...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 2.8yrs | US$3.78m | 0.66% $ 3.7m | |
| Chief Legal Officer | 2.1yrs | US$1.57m | 0.14% $ 773.5k | |
| CFO & Treasurer | less than a year | Nessun dato | Nessun dato | |
| Vice President of Investor Relations & Corporate Communications | 3.9yrs | Nessun dato | Nessun dato | |
| Chief People Officer | 2.1yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Manufacturing | 3.5yrs | Nessun dato | Nessun dato | |
| Chief Commercial Officer | 3.5yrs | US$1.82m | 0.11% $ 600.4k | |
| Consultant | 2.5yrs | US$2.52m | 0.016% $ 93.7k | |
| Senior Vice President of Regulatory Affairs & Quality | 2.5yrs | Nessun dato | Nessun dato | |
| Senior VP & Chief of Staff | 2.5yrs | Nessun dato | Nessun dato | |
| Senior VP of Finance & Corporate Controller | 9.4yrs | Nessun dato | 0.050% $ 285.2k |
2.5yrs
Durata media
54yo
Età media
Gestione esperta: Il team dirigenziale di ZVRA è considerato esperto (durata media dell'incarico 2.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 2.8yrs | US$3.78m | 0.66% $ 3.7m | |
| Independent Director | 3.3yrs | US$243.99k | 0% $ 0 | |
| Independent Chair | 4.9yrs | US$304.68k | 0.0066% $ 37.6k | |
| Member of Scientific and Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 3.3yrs | US$246.91k | 0.21% $ 1.2m | |
| Independent Director | 3.3yrs | US$249.68k | 0.0030% $ 17.3k | |
| Chairman of Scientific and Medical Advisory Board | 19.5yrs | Nessun dato | Nessun dato | |
| Member of Scientific & Medical Advisory Board | no data | Nessun dato | Nessun dato | |
| Co-Chair of Physician Advisory Council | 12.8yrs | Nessun dato | Nessun dato | |
| Co-Chair of Physician Advisory Council | 12.8yrs | Nessun dato | Nessun dato | |
| Independent Director | 2.9yrs | US$252.18k | 0.034% $ 192.8k | |
| Independent Director | 2.5yrs | US$244.68k | 0.034% $ 192.8k |
3.3yrs
Durata media
59yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ZVRA sono considerati esperti (durata media dell'incarico 3.3 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/31 03:03 |
| Prezzo dell'azione a fine giornata | 2026/07/31 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Zevra Therapeutics, Inc. è coperta da 17 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Kenneth Trbovich | Brean Capital Historical (Janney Montgomery) |
| Kambiz Yazdi | BTIG |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |